Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
It’s been a pretty good year for biotech initial public offerings (IPOs), with two Bay Area biotechs marking numbers eight and nine for the area.
Cambridge, Massachusetts-based Biogen exercised its option to acquire additional shares of Samsung Bioepis, a joint venture with Samsung BioLogics that was founded in 2012.
Amazon is making a foray into an online pharmacy. Amazon is buying PillPack, an online pharmacy that allows customers to buy drugs in pre-made doses.
A group of Takeda Pharmaceutical shareholders’ bid to halt the acquisition of Dublin-based Shire failed to gain traction.
Shares of Akebia Therapeutics are up more than 10 percent in premarket trading after the company announced it struck a merger agreement with Keryx Biopharmaceuticals, Inc. to create a company expected to be a leader in the development of renal disease therapies.
Cambridge, Massachusetts-based Neon Therapeutics is launching an initial public offering (IPO) of 6,250,000 shares of common stock at a price offering of $16 per share.
Three months after securing $100 million in a crossover financing round, Cambridge, Mass.-based Rubius Therapeutics is looking at a $200 million initial public offering to support its personalized red blood cell therapeutics program.
GE Healthcare will be spun off from General Electric (GE) within the next 12 to 18 months. It will likely be based in Chicago, where its global headquarters are located.
Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month.